NKI-AVL
L.J. Boersma, Ph. Poortmans, J.W. Leer, H. Bartelink
NKI-AVL trialbureau
Plesmanlaan 121
1066 CX Amsterdam
Tel 020 5122668
Fax 020 5122679
E-mail trial@nki.nl
RT quality control via dummy runs
Funding by KWF
Follow-up: Vanaf 10 jaar – 20 jaar na RT: – 1x per 2 jaar, en dat mag telefonisch -op 14 en 20 jaar “live”, en dan ook cosmetiek foto
Randomization: Arm A: standard RT + high boost dose (26 Gy) Arm B: standard RT + low boost dose (16 Gy)
A. The main objective is to compare the effect of a high boost dose (26 Gy) with a low boost dose (16 Gy) in breast conserving therapy, on the local recurrence rate. B. The secondary objective is to compare the effect of the high boost dose (26 Gy) with a low boost dose (16 Gy) in breast conserving therapy, on the cosmesis. Additional objectives: To test the genotypic and phenotypic profiles of breast tumors in young patients with invasive breast cancer, and its relation to: a. Local recurrence after BCT b. Lymph node metastases c. Distant metastases and survival d. Radiosensitivity e. Age To determine whether improved genotypic and phenotypic profiles can be determined related to the trial endpoints.
Primary endpoint:
Secondary endpoint:
Age ≤ 50 years, pT1-2pN0-2a M0; Breast conserving surgery
